ADPT vs. TWST, TXG, VCYT, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, and TLX
Should you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Twist Bioscience (TWST), 10x Genomics (TXG), Veracyte (VCYT), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), and Telix Pharmaceuticals (TLX). These companies are all part of the "medical" sector.
Adaptive Biotechnologies vs. Its Competitors
Twist Bioscience (NASDAQ:TWST) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.
Twist Bioscience presently has a consensus target price of $50.40, suggesting a potential upside of 38.58%. Adaptive Biotechnologies has a consensus target price of $10.57, suggesting a potential downside of 4.42%. Given Twist Bioscience's higher probable upside, research analysts clearly believe Twist Bioscience is more favorable than Adaptive Biotechnologies.
Adaptive Biotechnologies has lower revenue, but higher earnings than Twist Bioscience. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Twist Bioscience. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 5 mentions for Twist Bioscience. Adaptive Biotechnologies' average media sentiment score of 0.56 beat Twist Bioscience's score of 0.54 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.
Twist Bioscience has a net margin of -54.98% compared to Adaptive Biotechnologies' net margin of -74.84%. Twist Bioscience's return on equity of -33.48% beat Adaptive Biotechnologies' return on equity.
Twist Bioscience has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.
99.2% of Adaptive Biotechnologies shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Adaptive Biotechnologies beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.
Get Adaptive Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptive Biotechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:ADPT) was last updated on 7/15/2025 by MarketBeat.com Staff
Free ADPT Stock Alerts